Ascendis Pharma is a clinical stage biopharmaceutical company applying its TransCon technology to develop a pipeline of long-acting prodrug therapies with best-in-class profiles to address large markets with significant unmet medical needs.
|Recent News||More >>|
Ascendis Pharma Provides Update on Rare Disease Endocrinology Pipeline and Presents Initial Phase 1 Data for TransCon PTH
Ascendis Pharma Announces Completion of Target Enrollment in Phase 3 Trial of TransCon Growth Hormone for Pediatric Growth Hormone Deficiency
Ascendis Pharma A/S Announces Participation in 36th Annual J.P. Morgan Healthcare Conference
|Upcoming Events||More >>|
|There are currently no events scheduled.|
|Primary IR Contact|
|Scott T. Smith|
Chief Financial Officer
Data provided by Nasdaq. Minimum 15 minutes delayed.